Treating

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
Saturday, February 17, 2024
Science, Research, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Mental Health, Clinical Trials, Artificial intelligence, Central nervous system disease, Pain, IGC, Loss, GMP, Composition, Treating, Cannabinoid, University, PPE, Certification, Administration, Patent, Patient, CBD, THC, LMP, Agitation, American University, Dementia, Bank statement, Somatic symptom disorder, Human, European Patent Convention, Pharmaceutical industry

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).
  • IGC is optimistic that the success in Mexico can pave the way for additional patent approvals in the U.S. and Europe.
  • We are working hard to obtain interim results in 2024.
  • With modest pricing and conservative market penetration IGC-AD1 can potentially be a block buster drug,” said Ram Mukunda, CEO of IGC Pharma.

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

Retrieved on: 
Tuesday, January 23, 2024
Technology, Surgery, Medical Devices, Science, Genetics, Clinical Trials, FDA, Biotechnology, Health, Health Technology, Research, Other Technology, Other Health, Radiology, Pharmaceutical, Artificial Intelligence, Oncology, Patient, Therapy, Compound, Intelligence, Malignancy, Cancer, Lung cancer, Porphyrin, Disease, Controller, Grant, Physician, Treating, BIAF, Lung, Pharmaceutical industry

The Indian patent, titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” is an important addition to bioAffinity Technologies’ patent portfolio, which includes 16 awarded U.S. and foreign patents and 23 pending patent applications related to its porphyrin-based diagnostic platform and cancer treatment therapeutics.

Key Points: 
  • The Indian patent, titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” is an important addition to bioAffinity Technologies’ patent portfolio, which includes 16 awarded U.S. and foreign patents and 23 pending patent applications related to its porphyrin-based diagnostic platform and cancer treatment therapeutics.
  • “India’s patent is an acknowledgement of the value of our ongoing research, development and commercialization of porphyrin-based diagnostics and targeted treatments for lung cancer and other diseases,” bioAffinity Technologies’ President and CEO Maria Zannes said.
  • “We are committed to improving the outcome for cancer patients around the world, beginning with lung cancer, the deadliest cancer killer.
  • Physicians use CyPath® Lung for patients at high risk for developing lung cancer, often after recommended screening reveals indeterminate pulmonary lung nodules that may or may not be malignant.

Immorta Bio Welcomes Dr. Vlad Bykoriz as its Chief Medical Officer

Retrieved on: 
Tuesday, January 23, 2024
Disease, Risk management, Patient, MD, Culture, Medical director, Big Pharma, Pfizer, IND, CMO, Doctor of Philosophy, Boehringer Ingelheim, Treating

MIAMI BEACH, Fla., Jan. 23, 2024 /PRNewswire/ -- Immorta Bio, Inc. announced today that Vlad Bykoriz, MD, PhD, has joined the company's management team. Together with other executives, Dr. Bykoriz will be defining the products pipeline and their development strategies. He will be building Immorta Bio preclinical and clinical capabilities, ensuring adherence to ethical guidelines and regulatory compliance, and ultimately helping to bring Immorta Bio innovative therapies to patients.

Key Points: 
  • He will be building Immorta Bio preclinical and clinical capabilities, ensuring adherence to ethical guidelines and regulatory compliance, and ultimately helping to bring Immorta Bio innovative therapies to patients.
  • "We are extremely excited about finding such a strong CMO as Dr. Vlad Bykoriz.
  • Equally important is that, in addition to his professional and managerial skills, Vlad fits into the Immorta Bio organization and culture perfectly."
  • Dr. Vlad Bykoriz received his MD degree from Kiev Medical University and his PhD from the Kiev Institute of Cardiology.

XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease

Retrieved on: 
Wednesday, January 3, 2024
DN, Immunoglobulin A, IgA nephropathy, Kidney disease, Diabetic nephropathy, Uric acid, Trial of the century, Oxipurinol, Therapy, Autosome, Pharmacokinetics, Focal segmental glomerulosclerosis, Patent, Chronic kidney disease, ADPKD, Treating, Study, Polycystic kidney disease, XRX, Safety, Lupus nephritis, XOI, CKD, Pharmaceutical industry

CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“CKD”).

Key Points: 
  • CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“CKD”).
  • This patent is designed to protect new discoveries and strategies for the treatment of individuals with varied degrees of kidney function in the setting of CKD.
  • This patent application is intended to claim new opportunities to enhance how the xanthine oxidase inhibitor class of drugs may be dosed in the future.
  • Importantly, how to further improve the safe and effective administration of this class of drugs, including oxypurinol.”

Immorta Bio Announces Personalized Progenitor Cell Platform for Organ Specific Regeneration

Retrieved on: 
Tuesday, January 2, 2024
PPC, CSO, Cell, Patent, MIAMI, Treating, Tissue, Stem cell, Vaccine

MIAMI BEACH, Fla., Jan. 2, 2024 /PRNewswire/ -- Immorta Bio, Inc. announced today its Personalized Progenitor Cell (PPC) platform and filing of associated intellectual property. In addition to proprietary know-how and trade secrets, the company filed patent application #63/599440.

Key Points: 
  • MIAMI BEACH, Fla., Jan. 2, 2024 /PRNewswire/ -- Immorta Bio, Inc. announced today its Personalized Progenitor Cell (PPC) platform and filing of associated intellectual property.
  • "One of the limitations of commonly used stem cell therapies is their reliance on in vivo differentiation," said Thomas Ichim, President and CSO of Immorta Bio.
  • Those cells are then administered in quantities required to achieve organ rejuvenation, a state, Immorta Bio calls, Stem Cell Revivify™.
  • "Immorta Bio is focused on Treating Diseases of Aging and Treating Aging as Disease™," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio.

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s

Retrieved on: 
Tuesday, December 19, 2023
Research, General Health, Cannabis, Pharmaceutical, Mental Health, Technology, Natural Resources, Artificial Intelligence, Health Technology, Clinical Trials, Science, Neurology, Health, Quality of life, Alzheimer's disease, Agitation, Caregiver, Caregiver burden, Composition, Patent, Treating, Public, CNS, Disorder, LMP, CB1, Somatic symptom disorder, Patient, IGC, Central nervous system, Pharmaceutical industry

IGC Pharma is currently progressing a Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer’s disease, the most common form of a central nervous system disorder (CNS).

Key Points: 
  • IGC Pharma is currently progressing a Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer’s disease, the most common form of a central nervous system disorder (CNS).
  • IGC Pharma has strategically sought patent protection for the IGC-AD1 formulation in many jurisdictions including the U.S., Europe, Canada, and Mexico.
  • Today’s announcement of the issuance of the patent for the drug formulation that targets Central Nervous System (CNS) Disorders marks an important milestone in helping set the stage for potential commercialization.
  • IGC Pharma is currently pursuing five drug assets targeting the treatment of agitation related to symptoms of Alzheimer's disease.

IGC Pharma Reports Second Quarter Fiscal 2024 Results

Retrieved on: 
Monday, November 13, 2023
Agriculture, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Mental Health, Cannabis, Clinical Trials, Composition, Shingles, Fibromyalgia, Cannabinoid, Research, NYSE, Treating, Scleroderma, IND, Epilepsy, Administration, Patient, IGC, Intelligence, Canadian Intellectual Property Office, Agitation, Dementia, LMP, Psoriatic arthritis, Human, Pain, Patent, Pharmaceutical industry, Cryptocurrency

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).
  • Revenue in Q2 FY2024 increased 44% to approximately $291,000 compared to the same quarter in FY2023 at roughly $202,000.
  • In the first six months of FY2024, revenue doubled to about $846,000 from about $414,000 compared to the prior year’s six-month period.
  • The Company continues to drive progress with ten sites in the United States and Canada, currently conducting the trial.

Venvalo Group Launches Immorta Bio, Inc Aimed at Providing Unlimited Personalized Cells for Treating Diseases of Aging and Treating Aging as Disease™

Retrieved on: 
Wednesday, December 6, 2023
Disease, Treating, CSO, Patient, Regenerative medicine, FDA, Multiple organ dysfunction syndrome, Heart failure, MIAMI, Liver failure, Cell, Pharmaceutical industry, Vaccine, Ageing

MIAMI BEACH, Fla., Dec. 6, 2023 /PRNewswire/ -- Venvalo Group announced today formation of Immorta Bio, Inc, a regenerative medicine company dedicated to providing patient specific therapeutic solutions for Treating Diseases of Aging and Treating Aging as Disease™.

Key Points: 
  • MIAMI BEACH, Fla., Dec. 6, 2023 /PRNewswire/ -- Venvalo Group announced today formation of Immorta Bio, Inc, a regenerative medicine company dedicated to providing patient specific therapeutic solutions for Treating Diseases of Aging and Treating Aging as Disease™.
  • "As we become older, a number of ailments accumulate, and it is inevitable that eventually you will succumb to one or a combination of those.
  • Solving the issue of diseases of aging is solving the aging itself," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio.
  • "We are developing personalized stem cell technologies that provide the greatest promise in the fight against diseases of aging."

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Retrieved on: 
Monday, October 30, 2023
ASX, MSA, Research, DTI, MRI, Tax, Neuroimaging, Biomusic, International Congress on Tuberculosis, DMC, Patent, Biomarker, MDS, Pathology, R, Data monitoring committee, Drug development, Pharmacokinetics, Multiple system atrophy, Australian Taxation Office, Research and Development Tax Incentive, Disease, ATH, European Patent Office, SAN, Movement disorder, Brain, Safety, European Patent Convention, Patient, Treating, Diagnosis, Vanderbilt University Medical Center, Iron, Pharmaceutical industry, Alterity

MELBOURNE, Australia and SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2023 (Q1 FY24).

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2023 (Q1 FY24).
  • In addition, an independent Data Monitoring Committee (DMC) recommended that the trial continue as planned and they expressed no concerns about safety.
  • Today, Alterity announced that screening has closed for its ATH434-201 Phase 2 clinical trial, an important step to completing enrollment in the study.
  • 3938364 covers more than 150 novel pharmaceutical compositions that are designed to redistribute the excess iron implicated in neurodegenerative diseases.

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s

Retrieved on: 
Wednesday, August 23, 2023
Drug development, European Patent Bulletin, Opposition procedure before the European Patent Office, Pathology, ASX, Brain, ATH, Treating, Patent, Iron, SAN, European Patent Convention, Therapy, Disease, Pharmaceutical industry, Alterity

MELBOURNE, Australia and SAN FRANCISCO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition of matter patent.

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition of matter patent.
  • The patent secures broad protection over a new class of iron chaperone drug candidates for treating major neurodegenerative diseases.
  • “Through restoration of normal iron balance in the brain, we have the potential to slow disease progression of diseases including Parkinson’s and Alzheimer’s.
  • The composition of matter patent covers more than 150 novel pharmaceutical compositions that are designed to redistribute the excess iron implicated in neurodegenerative diseases.